Q3 2016 · 10-Q
Revenue$374.18M$374.18M +9.8% vs Q3 2015−1.8% vs Q2 2016
Net Income$89.83M$89.83M +2.1% vs Q3 2015−21.5% vs Q2 2016
EPS Diluted$1.45$1.45 +4.3% vs Q3 2015−21.6% vs Q2 2016
Gross Profit$347,310,000+11.9%
Operating Income$136,253,000+3.6%
Operating Cash Flowderived$133,028,000−24.0%
Free Cash Flowderived$130,646,000−23.1%
Margins · derived
Gross margin92.8%+1.8 pt vs Q3 2015
Operating margin36.4%−2.2 pt vs Q3 2015
Net margin24.0%−1.8 pt vs Q3 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2016 | Q3 2015 | Q3 2014 | Q3 2013 |
|---|---|---|---|---|
| Revenue | $374.18M | $340.87M | $306.58M | $232.16M |
| Net Income | $89.83M | $87.96M | $25.77M | $75.41M |
| EPS Diluted | $1.45 | $1.39 | $0.41 | $1.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR